Tg Therapeutics (TGTX) Cash from Financing Activities (2011 - 2026)

Tg Therapeutics' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $390.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 6504.93% year-over-year to $390.8 million; the TTM figure through Mar 2026 stood at $307.2 million (up 150.95% YoY), while the FY2025 annual figure was -$89.7 million, down 169.81% from the prior year.
• Cash from Financing Activities was $390.8 million for Q1 2026 at Tg Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $390.8 million in Q1 2026 to a low of -$78.2 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $29.5 million across 5 years, with a median of $135000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities soared 34749.63% in 2023, then plunged 607100.0% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $49000.0 in 2022, then slumped by 102.04% to -$1000.0 in 2023, then slumped by 607100.0% to -$6.1 million in 2024, then jumped by 117.42% to $1.1 million in 2025, then surged by 36840.36% to $390.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $390.8 million (Q1 2026), $1.1 million (Q4 2025), and -$78.2 million (Q3 2025), per Business Quant data.